What Is KPV Peptide?

KPV is the common name for a tripeptide — a chain of just three amino acids, lysine-proline-valine — that corresponds to the tail end of a much larger hormone called alpha-melanocyte-stimulating hormone (alpha-MSH). It has never been tested in a published human clinical trial, and researchers have studied it almost entirely in cell cultures and rodents.

What KPV actually is

The name KPV is shorthand for its sequence under the standard one-letter amino acid code: K (lysine), P (proline), V (valine). Chemists also label it alpha-MSH(11-13), because it matches amino acids 11 through 13 — the last three — of the 13-amino-acid hormone alpha-MSH. As sold by research-chemical suppliers such as Cayman Chemical, the free tripeptide (commonly supplied as a trifluoroacetate salt) has the formula C16H30N4O4 with a free-base molecular weight of about 342.4 daltons, and vendor listings for it explicitly state it is "not for human or veterinary use." It is not a vitamin, a supplement ingredient with its own safety monograph, or an approved medicine; it is a laboratory reagent built to isolate one small piece of a hormone's chemistry.

Alpha-MSH itself is produced naturally in the body, derived from a larger precursor protein and involved in skin pigmentation and in regulating inflammation and immune signaling. KPV is not something the body produces or releases on its own in meaningful amounts; researchers synthesize it to test whether alpha-MSH's effects can be reproduced, or isolated, with just its three C-terminal amino acids rather than the whole hormone.

Where the research line started

The idea that alpha-MSH's effects might be concentrated in its tail end goes back more than 40 years. A 1984 study in the journal Peptides, by researchers Richards and Lipton, reported that alpha-MSH(11-13) reduced fever in rabbits when given either directly into the brain or into the body generally, suggesting the "antipyretic message" of the full hormone lived mostly in that short fragment. Later work out of the same research lineage, a 1989 study by Hiltz and Lipton presented at a FASEB meeting, found that the tripeptide also reduced inflammatory ear swelling in mice caused by a skin-irritant chemical, in a dose-related way, compared with saline. Those two findings — less fever, less swelling — set the research agenda that continues today: can a three-amino-acid fragment reproduce alpha-MSH's broader anti-inflammatory behavior on its own.

What has actually been studied, and in what models

The best-known modern study of KPV is a 2008 paper in the journal Inflammatory Bowel Diseases by a University of Münster group led by Kannengiesser and Kucharzik. The researchers gave KPV to mice with two different induced forms of colitis — one triggered by a chemical irritant in drinking water, the other by transferring a subset of immune cells into mice that lack a normal immune system. In both models, KPV-treated mice recovered body weight faster and showed less inflammatory tissue damage than untreated mice. In a third group of mice engineered to lack a working melanocortin-1 receptor — the receptor alpha-MSH is best known for activating — KPV still protected the animals from colitis, which the authors took as evidence that at least part of KPV's effect does not run through that specific receptor.

A 2007 review in Annals of the Rheumatic Diseases, co-written by Thomas Luger and Thomas Brzoska of the University of Münster, summarizes the broader cell-culture and animal literature on KPV and a related tripeptide. The reviewers describe KPV as reducing activation of NF-kB, a protein complex that switches on inflammatory genes, and lowering production of several inflammatory signaling molecules, including TNF-alpha, IL-6 and IL-1-beta, in laboratory cell models. Separately, the review and other laboratory reports describe KPV showing activity against bacteria and yeast, including Staphylococcus aureus and Candida albicans, in cell-based assays — and note that a linked double version of the peptide has been examined for antimicrobial use. Notably, the review itself says it is "not yet clear" whether KPV binds the melanocortin receptors at all, which leaves its exact mechanism an open scientific question even among the researchers who study it most closely.

Across all of this, the pattern is consistent: KPV's research record is in petri dishes and in mice, not in people. No completed, published human clinical trial testing KPV's safety or effects has been identified in the literature search for this post.

Regulatory status

KPV is not an FDA-approved drug for any use, and it carries no over-the-counter or dietary-supplement status either — it exists in a regulatory gap occupied by research chemicals. In July 2026, the FDA's Pharmacy Compounding Advisory Committee voted, 8 to 6 with one abstention, to recommend adding KPV to the agency's list of bulk substances that compounding pharmacies may use, alongside six other peptides under review that meeting. The FDA's own career scientific staff had recommended against listing any of them, citing thin or absent human safety and effectiveness data, according to coverage of the vote.

That committee recommendation is advice, not law, and on its own it changes nothing about KPV's legal status. What has changed is enforcement posture: on October 28, the Department of Health and Human Services filed a signed notice saying it does not intend to pursue enforcement action against licensed pharmacies, facilities or physicians that compound six specific peptides, including KPV, under certain conditions — a policy the Journal covered in detail when the notice was filed. That notice explicitly states it does not constitute FDA approval of any peptide and creates no legal rights. KPV is one of six peptides swept up in that same policy shift, alongside BPC-157, which has followed a similar regulatory arc of its own.

What is known versus unknown

Known: KPV is a precisely defined three-amino-acid fragment of alpha-MSH with a research record stretching back to 1984, showing reduced fever and inflammatory swelling in early studies and reduced colitis severity in a well-designed 2008 mouse study, plus laboratory evidence of effects on inflammatory signaling and some antimicrobial activity in cell cultures. Known: it is not FDA-approved, is sold explicitly as a research-only chemical, and is one of the peptides now covered by an interim, reversible federal enforcement-discretion policy rather than a formal approval.

Unknown: almost everything about how KPV behaves in a human body. There is no published human trial establishing a safe dose range, how the peptide is absorbed or broken down in people, or whether the anti-inflammatory and antimicrobial effects seen in mice and petri dishes occur in humans at all. Even the basic question of which receptor or receptors KPV acts through — the classical melanocortin pathway, something else, or some mix of pathways — remains genuinely unsettled in the primary literature, not just undersold by secondary sources.

What this means for researchers

KPV illustrates a pattern that shows up repeatedly in peptide research: a genuinely interesting, decades-old mechanistic story in animals and cells, paired with essentially no human clinical data and a regulatory status that has moved faster than the underlying science. The 2008 colitis study and the NF-kB mechanism work are real, peer-reviewed findings worth taking seriously as hypotheses — they are not worth mistaking for evidence of what KPV does in a person.

The practical thing to track going forward is the same for KPV as for the other peptides swept into October's enforcement-discretion notice: whether the public comment period on that policy produces new safety reporting, and whether the FDA's own scientific staff — who argued against listing KPV in the first place — revisit that position based on anything other than a committee vote. Until then, KPV's evidence base is exactly where it was after 2008: solid in rodents, open to interpretation on mechanism, and silent on humans.